Potassium Disturbances: Hypokalemia and Hyperkalemia — Comprehensive Study Notes
Overview
Potassium disturbances arise when there is an imbalance between intake, distribution (intracellular vs extracellular), and excretion. Most potassium is intracellular, so small shifts between the intracellular and extracellular space can have large effects on cellular excitability, particularly in muscle and nerve tissue, including the heart. Potassium abnormalities are common and clinically important but are treatable once the underlying pathophysiology is understood. The lecture by Vincent Lee covers hypokalemia and hyperkalemia, their physiological impact, typical clinical and ECG findings, causes, and management options.
Hypokalemia (low plasma potassium)
Hypokalemia is defined as a plasma potassium concentration below the local laboratory reference range, with many labs using the cutoff [K^+]_{ ext{plasma}} < 3.5\ ext{mmol/L}. It alters transmembrane potential in cells most dependent on potassium homeostasis—primarily skeletal muscle, smooth muscle, and nerves—and this has downstream effects on both neuromuscular and cardiac function.
Initially, hypokalemia tends to make the transmembrane potential more negative (hyperpolarization). However, it subsequently leads to enhanced sodium channel activation that increases membrane excitability. Clinically, this manifests as skeletal muscle weakness and a spectrum of cardiac effects. On the ECG, one can see a fall in T-wave height, the appearance of U waves, and as potassium levels drop further, ectopics or ventricular arrhythmias such as ventricular tachycardia or fibrillation. Atrial and ventricular ectopics, sinus bradycardia, paroxysmal atrioventricular junctional tachycardia, and AV block may also occur.
Hypokalemia also affects gut muscles, potentially causing ileus and a pseudo-obstruction. Chronic hypokalemia is associated with nephrogenic diabetes insipidus due to fibrosis within the tubular interstitial compartment, and this is observed in chronic conditions linked to hypokalemia such as Gitelman syndrome or Bartter syndrome.
To illustrate the effect on cardiac myocytes, consider the typical myocardial action potential. The resting membrane potential (RMP) of a cardiac cell is around During contraction (phase 0), depolarization is driven by a marked influx of Na⁺ through voltage-gated Na⁺ channels. Repolarization involves closing Na⁺ channels and the orchestrated movement of K⁺ and Ca²⁺ through their respective channels. In hypokalemia, the membrane potential becomes more negative initially, meaning the cell is harder to depolarize at first, but the increased availability of Na⁺ channels leads to a net increase in excitability. There is also a delay in ventricular repolarization, which prolongs the refractory period and predisposes to reentrant arrhythmias.
A representative ECG cited in the lecture shows a patient with a plasma potassium near , with markedly flattened or inverted T waves and prominent U waves, which are characteristic findings in hypokalemia.
Causes of hypokalemia
Hypokalemia can result from potassium redistribution, reduced intake, or excess loss. Redistribution can occur with marked alkalosis, which drives potassium into cells. Reduced intake alone is usually insufficient to cause significant hypokalemia because the kidney conserves potassium efficiently, but it can contribute in conjunction with losses.
The most common causes of hypokalemia relate to loss, either renal or gut. Renal potassium losses can be due to diuretics acting at various nephron sites (as discussed in prior lectures) or primary hyperaldosteronism, which increases renal potassium excretion. Gastrointestinal losses (vomiting, diarrhea) cause potassium loss with accompanying volume depletion; volume contraction stimulates aldosterone release, further increasing renal potassium excretion. In hypovolemia, aldosterone rises and urinary potassium excretion increases despite whether the primary potassium loss was GI or renal.
The talk also touches on specific chronic conditions associated with hypokalemia, such as Gitelman syndrome and Bartter syndrome, which are characterized by renal potassium wasting.
There is a vignette of Conn’s syndrome (primary hyperaldosteronism) described in the transcript as a hypertension-related condition with excess aldosterone acting at the nephron’s principal cells. The image/concept presented notes that hyperkalemia is common but not universal in Conn’s syndrome (about 30% according to the talk). Pathophysiologically, aldosterone increases sodium reabsorption via ENaC in the distal nephron and stimulates Na⁺/K⁺ ATPase activity, promoting potassium loss. This section, however, contains a clinically important point of confusion: in typical physiology, Conn’s syndrome more commonly causes hypokalemia rather than hyperkalemia owing to vigorous renal potassium wasting. The note below clarifies this discrepancy.
Important clinical nuance (note on the transcript)
In the transcript, Conn’s syndrome is described as often producing hyperkalemia (about 30% of cases). In standard medical understanding, primary hyperaldosteronism more commonly causes hypokalemia due to increased renal potassium excretion. When studying the transcript, be aware that this portion may reflect a misstatement and should be cross-checked with authoritative references.
Management of hypokalemia
Treatment aims to correct the underlying cause and replenish potassium. Acute management includes stabilizing the cell membrane (especially if there is concurrent dysrhythmia). The lecture mentions calcium salts (e.g., calcium gluconate) to stabilize the myocardium if needed. Potassium replacement is accomplished with potassium chloride, either orally (e.g., slow K) or intravenously, recognizing the correct formulation to avoid metabolic disturbances. Be mindful that certain potassium salts (such as potassium bicarbonate) can shift bicarbonate metabolism and may worsen potassium disturbances (e.g., by exacerbating metabolic alkalosis).
Other approaches include shifting potassium into cells using insulin (with glucose to avoid hypoglycemia), and beta-2 adrenergic agonists (e.g., salbutamol). Alkalinization of plasma with bicarbonate can also promote intracellular potassium shift. When oral or intravenous replacement is insufficient or impractical, renal elimination (diuretics) or gut binding of potassium to reduce absorption can be employed, and dialysis is a consideration in severe or refractory cases. A potassium-sparing diuretic such as amiloride can limit renal potassium loss by antagonizing ENaC in the principal cells of the distal nephron.
Hyperkalemia (high plasma potassium)
Hyperkalemia is defined as plasma potassium concentration above the reference range, typically around [K^+]_{ ext{plasma}} > 5\ \text{mmol/L}, though exact cutoffs vary by laboratory reference limits. Hyperkalemia has profound effects on skeletal muscle and cardiac tissue and can manifest clinically as weakness or paralysis and life-threatening cardiac arrhythmias. On ECG, early hyperkalemia produces peaked T waves and a progressively widened QRS complex, and in severe cases a sine wave pattern with very wide QRS and absence of P waves may occur, signaling urgent treatment.
Mechanistically, the cell membrane potential becomes less negative (depolarized) in hyperkalemia, which initially increases membrane excitability. However, as hyperkalemia progresses, there is a reduction in the availability of voltage-gated Na⁺ channels, leading to reduced excitability and impaired conduction, which can manifest as conduction abnormalities and bradyarrhythmias.
Classic ECG and clinical examples
An ECG with a potassium around shows tall, peaked T waves and slight QRS widening. A more severe case with potassium near can show a sine wave pattern with no visible P waves and markedly broadened QRS, signaling an urgent need for treatment.
Causes of hyperkalemia
Hyperkalemia can be spurious if blood obtained for potassium measurement is hemolyzed; this releases intracellular potassium into the sample, artificially elevating the reading (the lecture notes pink color as a sign of hemolysis).
Redistribution of potassium can occur with acidosis (high hydrogen ion concentration) or lack of insulin (e.g., diabetic ketoacidosis). Beta-adrenergic blockade can also raise potassium by reducing cellular uptake. Increased dietary potassium intake, particularly in patients with reduced kidney function, can overwhelm renal excretory capacity. Renal causes include reduced glomerular filtration rate (GFR) or tubular secretory failures, including aldosterone deficiency (as in Addison’s disease) or blockade of the epithelial sodium channel (e.g., amiloride) or renal tubular acidosis. In Addison’s disease, autoimmune adrenal insufficiency leads to low aldosterone, hyponatremia, hypotension, and hyperkalemia due to reduced potassium excretion. The transcript also mentions renal cases with normal GFR but impaired distal potassium handling and reduced aldosterone activity.
Management of hyperkalemia
Emergency management includes stabilizing the cardiac membrane with calcium salts (commonly calcium gluconate), followed by strategies to shift potassium into cells (insulin with glucose to prevent hypoglycemia; beta-2 agonists such as salbutamol; and bicarbonate in acidotic patients to promote intracellular shifts). To remove potassium from the body, several approaches are used: diuretics to enhance renal excretion, gastrointestinal binding of potassium (e.g., resins or newer agents), and in severe or refractory cases, dialysis. The transcript notes these general strategies and emphasizes addressing the underlying cause (e.g., stopping or treating GI losses, correcting acidosis, treating DKA, addressing adrenal insufficiency).
Connections, implications, and practical considerations
Potassium homeostasis depends on intake, intracellular distribution, and renal/colonic excretion. Disturbances can arise from shifts between compartments (redistribution), decreased intake with increased losses, or impaired excretion.
Cardiac electrophysiology is particularly sensitive to potassium, as reflected in resting membrane potential, conduction velocity, and refractoriness. This underpins the characteristic ECG changes in hypo- and hyperkalemia and explains the risk of dangerous arrhythmias.
The management strategies emphasize reversing the underlying cause, stabilizing the myocardium, and then correcting potassium levels with either shift strategies or removal strategies. Dialysis is a critical option for patients with renal failure or severe, refractory hyperkalemia.
Real-world management requires careful assessment of volume status, renal function, acid-base balance, and concurrent medications (e.g., diuretics, insulin, beta-blockers) that can influence potassium handling.
Ethical and practical implications include the need for rapid diagnosis and initiation of treatment in acute cases to prevent fatal arrhythmias, the importance of cross-checking statements that differ from standard physiology (e.g., Conn’s syndrome and hyperkalemia), and considering patient-specific factors (kidney function, GI losses, and comorbid endocrine disorders).
Summary
Hypokalemia and hyperkalemia are common, clinically significant, and eminently treatable potassium disturbances. Understanding how potassium distribution and excretion interact with cellular excitability clarifies the characteristic symptoms, ECG findings, and responses to therapy. Correctly identifying the underlying cause—whether redistribution, renal or GI loss, hormonal influences, or pseudo-elevation from sample handling—is essential for effective management and prevention of recurrence.